Compare EQH & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQH | BIIB |
|---|---|---|
| Founded | 1859 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.2B | 24.2B |
| IPO Year | N/A | 1991 |
| Metric | EQH | BIIB |
|---|---|---|
| Price | $46.01 | $181.61 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 23 |
| Target Price | $64.18 | ★ $176.48 |
| AVG Volume (30 Days) | ★ 2.9M | 1.9M |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 10.97 |
| Revenue | ★ $12,224,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $25.11 | $3.61 |
| Revenue Next Year | $5.01 | N/A |
| P/E Ratio | ★ N/A | $16.52 |
| Revenue Growth | ★ 13.38 | 4.77 |
| 52 Week Low | $41.39 | $110.04 |
| 52 Week High | $56.61 | $185.17 |
| Indicator | EQH | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 48.39 | 72.92 |
| Support Level | $44.30 | $174.53 |
| Resistance Level | $46.17 | $182.94 |
| Average True Range (ATR) | 1.25 | 5.22 |
| MACD | 0.27 | 0.25 |
| Stochastic Oscillator | 71.73 | 83.54 |
Equitable Holdings Inc is a financial services company in the U.S. The company provides variable annuities, tax-deferred investment and retirement plans, employee benefits, and protection solutions for individuals, families, and small businesses. Its business segments include Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. It generates the majority of its revenue from the Asset Management segment which provides diversified investment management and related solutions globally to a broad range of clients through three main client channels - Institutional, Retail, and Private Wealth.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).